ACB
Price
$5.08
Change
-$0.31 (-5.75%)
Updated
Aug 15 closing price
Capitalization
286.3M
81 days until earnings call
INCR
Price
$1.63
Change
-$0.03 (-1.81%)
Updated
Aug 15 closing price
Capitalization
88.86M
One day until earnings call
Interact to see
Advertisement

ACB vs INCR

Header iconACB vs INCR Comparison
Open Charts ACB vs INCRBanner chart's image
Aurora Cannabis
Price$5.08
Change-$0.31 (-5.75%)
Volume$1.61M
Capitalization286.3M
Intercure
Price$1.63
Change-$0.03 (-1.81%)
Volume$25.16K
Capitalization88.86M
ACB vs INCR Comparison Chart in %
Loading...
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACB vs. INCR commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a Hold and INCR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (ACB: $5.08 vs. INCR: $1.63)
Brand notoriety: ACB: Notable vs. INCR: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ACB: 99% vs. INCR: 75%
Market capitalization -- ACB: $286.3M vs. INCR: $88.86M
ACB [@Pharmaceuticals: Generic] is valued at $286.3M. INCR’s [@Pharmaceuticals: Generic] market capitalization is $88.86M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green whileINCR’s FA Score has 1 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • INCR’s FA Score: 1 green, 4 red.
According to our system of comparison, INCR is a better buy in the long-term than ACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 6 TA indicator(s) are bullish while INCR’s TA Score has 5 bullish TA indicator(s).

  • ACB’s TA Score: 6 bullish, 4 bearish.
  • INCR’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ACB is a better buy in the short-term than INCR.

Price Growth

ACB (@Pharmaceuticals: Generic) experienced а +13.39% price change this week, while INCR (@Pharmaceuticals: Generic) price change was +8.67% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.25%. For the same industry, the average monthly price growth was +10.98%, and the average quarterly price growth was +78.05%.

Reported Earning Dates

ACB is expected to report earnings on Nov 06, 2025.

INCR is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+4.25% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACB($286M) has a higher market cap than INCR($88.9M). INCR has higher P/E ratio than ACB: INCR (25.48) vs ACB (19.44). ACB YTD gains are higher at: 19.529 vs. INCR (2.516). ACB has higher annual earnings (EBITDA): 50.2M vs. INCR (-39.54M). ACB has more cash in the bank: 109M vs. INCR (20.3M). ACB has less debt than INCR: ACB (101M) vs INCR (151M). ACB has higher revenues than INCR: ACB (321M) vs INCR (273M).
ACBINCRACB / INCR
Capitalization286M88.9M322%
EBITDA50.2M-39.54M-127%
Gain YTD19.5292.516776%
P/E Ratio19.4425.4876%
Revenue321M273M118%
Total Cash109M20.3M537%
Total Debt101M151M67%
FUNDAMENTALS RATINGS
ACB vs INCR: Fundamental Ratings
ACB
INCR
OUTLOOK RATING
1..100
9226
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
61
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8994
PRICE GROWTH RATING
1..100
5952
P/E GROWTH RATING
1..100
925
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACB's Valuation (59) in the Pharmaceuticals Other industry is in the same range as INCR (61) in the Servicestothe Health Industry industry. This means that ACB’s stock grew similarly to INCR’s over the last 12 months.

ACB's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as INCR (100) in the Servicestothe Health Industry industry. This means that ACB’s stock grew similarly to INCR’s over the last 12 months.

ACB's SMR Rating (89) in the Pharmaceuticals Other industry is in the same range as INCR (94) in the Servicestothe Health Industry industry. This means that ACB’s stock grew similarly to INCR’s over the last 12 months.

INCR's Price Growth Rating (52) in the Servicestothe Health Industry industry is in the same range as ACB (59) in the Pharmaceuticals Other industry. This means that INCR’s stock grew similarly to ACB’s over the last 12 months.

INCR's P/E Growth Rating (5) in the Servicestothe Health Industry industry is significantly better than the same rating for ACB (92) in the Pharmaceuticals Other industry. This means that INCR’s stock grew significantly faster than ACB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBINCR
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
81%
Momentum
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
75%
MACD
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
72%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 6 days ago
73%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 19 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
61%
Bearish Trend 3 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SGPYY59.110.16
+0.27%
Sage Group plc (The)
MGHL1.47N/A
N/A
Morgan Group Holding Co.
CBYDF10.44N/A
N/A
Corby Spirit and Wine Ltd.
KSANF14.65N/A
N/A
Kansai Paint Co., Ltd.
TETAA16.00N/A
N/A
Teton Advisors Inc.

INCR and

Correlation & Price change

A.I.dvisor tells us that INCR and SNDL have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INCR and SNDL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCR
1D Price
Change %
INCR100%
-1.81%
SNDL - INCR
25%
Poorly correlated
-4.27%
ACB - INCR
24%
Poorly correlated
-5.75%
OGI - INCR
24%
Poorly correlated
-8.33%
DVAX - INCR
23%
Poorly correlated
+1.60%
SUPN - INCR
23%
Poorly correlated
+1.23%
More